Chapter 12 Daniel Costa: [11:38], the sentence

“So, as an example, for these three classes of EGFR uncommon mutations, there was a 2018 approval for the second-generation EGFR inhibitor afatinib at its 40 mg daily dose [7, 9], and this was based on a post-hoc analysis of the LUX-Lung 2, 3, and 6 registration trials of afatinib [7, 10].”

“So, as an example, for these three classes of EGFR uncommon mutations, there was a 2018 approval for the second-generation EGFR inhibitor afatinib at its 40 mg daily dose [7, 9], and this was based on a post-hoc analysis of the LUX-Lung 2, 3, and 6 registration trials of afatinib [7, 10] (Table 1).”

Chapter 14 Daniel Costa: [15:30], the sentence

“But in the two mutations that you mentioned, and that correlate with the preclinical work, the EGFR G719X and the EGFR S768I, the clinical responses, even when dose reductions are necessary, seem to be the most robust, really highlighting the preclinical work showing that these mutants, because of their structure–function properties, are most sensitive to this type of EGFR TKI inhibition [11].”

“But in the two mutations that you mentioned, and that correlate with the preclinical work, the EGFR G719X and the EGFR S768I, the clinical responses, even when dose reductions are necessary, seem to be the most robust, really highlighting the preclinical work showing that these mutants, because of their structure–function properties, are most sensitive to this type of EGFR TKI inhibition [1, 11, 12] (Table 1).”

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.